Intercept (ICPT) Positive Stance Maintained at RBC as Another PBC Competitor 'Falls to Wayside' (SHPG)
Tweet Send to a Friend
RBC Capital maintained an Outperform rating on Intercept Pharmaceuticals (NASDAQ: ICPT) with a price target of $490. Earlier Shire (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
